light jakafi revenu
investor skeptic ahead
report strong execut even jakafi soft
headlin number data approach trade
share continu impli investor doubt
trial success see highli favor risk reward
level maintain ow rate
in-lin result good commerci outlook overshadow
jakafi inventori nois caution report financi
mostli in-lin expect though fluctuat jakafi inventori
result sale slightli consensu estim execut
across aspect busi remain strong iclusig europ
revenu royalti revenu partner sale jakavi olumi
growth jakafi revenu guidanc midpoint
mostli in-lin consensu despit view reason well-
execut quarter share weaker investor posit ahead data
pivot trial epacadostat melanoma expect
top-line jakafi revenu light due inventori fluctuat underli
dynam remain strong report jakafi net revenu
essenti flat qoq come consensu
estim recal jakafi inventori slightli elev
see note exit reduct inventori held
distributor quantifi approxim half week result flat qoq
revenu manag note inventori revenu normal
rang half week sale repres revenu importantli
underli demand growth jakafi remain strong consist evidenc
yoy increas patient therapi addit guidanc
impli growth midpoint cite higher
proport pv patient earlier use mf associ longer
durat therapi key factor expect growth potenti use
gvhd data et contribut compani long term
outlook peak sale
addit revenu driver iclusig jakavi/olumi royalti strong
report revenu iclusig europ
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
consensu estim royalti jakavi sale grew
yoy estim novarti continu drive
ex-u adopt obtain approv countri mf
countri pv royalti partner lilli sale olumi baricitinib
total top estim quarter
investor cautiou head data data pivot echo-
trial epacadostat pembrolizumab frontlin melanoma expect
remain import clinic catalyst share addit
first potenti indic epacadostat melanoma gener
view key prove ground immunotherapi success import
valid epacadostat potenti tumor current level
share impli signific investor skeptic head data set
posit risk reward skew view
updat model rais jakafi iclusig estim
updat model reflect financi well updat expect
revenu expens increas estim us
jakafi revenu midpoint guidanc
rang also increas iclusig revenu estim
toward higher end guidanc base
strong commerci execut faster-than-anticip uptak europ
also increas expens estim account increas invest
broaden earli late-stag clinic develop program well
build global commerci infrastructur support epacadostat
top-line data pivot trial headlin catalyst
broad pipelin progress expect top-line data phase echo-
trial epacadostat/keytruda melanoma expect remain
key catalyst compani intend submit epacadostat nda
trial success set potenti approv earli
also plan pre-launch activ pend data
manag anticip expens top-line result also expect
trial jakafi steroid refractori acut gvhd
snda like incyt view key expans opportun jakafi
light increas incid gvhd signific mortal
patient data trial inhibitor
expect believ trial could basi regulatori
submiss given unmet need baricitinib resubmiss class
month review rheumatoid arthriti fda decis possibl
lilli believ adcom possibl expect epacadostat imfinzi
begin phase trial nsclc data io doublet trial
lastli advanc new candid target gitr
axl/mer clinic trial
see posit risk reward epacadostat level keep us ow
ahead data share challeng follow
announc secondari offer last fall investor concern
around risk-reward readout phase trial current
level see favor risk/reward readout
believ share could trade success outcom
trade trial fail
jak backbon lucr partnership fuel oncolog platform ow
lucr partnership fuel oncolog platform ow
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
next blockbust emerg early-stag oncolog pipelin
increas probabl success epacadostat melanoma nsclc rcc
hnscc bladder tumor commerci out-performance jakafi
base case earlier anticip us approv baricitinib ra
provid increment upsid addit collabor tumor type
epacadostat drive valu
increas penetr myelofibrosi polycythemia vera continu
drive jakafi revenu peak sale fuel industry-
lead engin baricitinib us approv ra result peak
royalti view epacadostat earli oncolog
pipelin increasingli meaning potenti sale epacadostat
risk-adjust indic probabl success
multipl clinic failur advers impact probabl success
epacadostat addit early-stag oncolog asset jakafi underperform
appear unlik reach compani peak guidanc
jakafi provid stabl revenu backbon
revenu grow annual
patent expiri driven continu uptak
myelofibrosi polycythemia vera
epacadostat increasingli meaning
piec thesi believ
epacadostat promis compound capabl
address multipl tumor type includ
melanoma lung renal head neck
bladder posit data tumor
type could lead addit upsid
driven potenti commerci execut
clinic asset drug discoveri platform
uniqu mid-cap biotech sector
possess deep pipelin
earli clinic pre-clin asset
addit commerci revenu royalti
key valuat driver commerci
execut approv drug well
perceiv clinic regulatori risk
phase data epacadostat/keytruda
melanoma
data brd pim program earli
risk achiev price
jakafi uptak less anticip
baricitinib fail obtain approv and/or
clinic failur epacadostat
baricitinib approv delay need sizabl outcom studi
pt includ jakafi sale myelofibrosi mf polycythemia vera pv
royalti jakavi sale europ iclusig sale all/cml europ royalti
baricitinib sale rheumatoid arthriti atop dermat epacadostat sale
melanoma lung kidney head neck bladder cancer graft-versus-host diseas
gvhd b-cell malign includ risk-adjust npv
robust earli clinic pre-clin asset well drug discoveri engin
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate line compani
termin growth rate model forecast revenu expens
opportun beyond anticip exclus period product
product ip beyond expiri assign termin valu
illion except per-shar data
otal jakafi evenu
otal aricitinib oyalti
product evenu
otal evenu
otal evenu
provis incom axe
